Thursday, September 05, 2013 9:21:57 PM
BioZone Labs BZNE is the next stock care of billionaire Doctor Phillip Frost to go bonkers. 40 cents was the very start, already at 70 cents, much more to come. Just like OPK doubled, SFES tripled, MSLP quadrupled, Doctor Frost knows how to invest and BZNE is already following suit. MusclePharm just invested at 40 cents a couple days ago so that will be a nice floor.
BZNE is a quintessential Doctor Frost stock. BZNE owns a platform technology with no drugs and no FDA approval process needed. QuSomes are patented lipids that increase the bioavailability of OTHER drugs or nutrients. Completely safe, already used in humans, zero complications.
BZNE's QuSomes technology can be paired with the sports supplements of MusclePharm, the drugs and nutraceuticals of Doctor Frost's Opko Health OPK, etc etc. Opko Health might just acquire the whole company, or build it up until it he helps it get sold to a pharma giant.
Recent COCP News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:15:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:00:46 PM
- Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/07/2024 08:30:24 PM
- Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:43 PM
- Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 02:53:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 01:00:40 PM
- Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:00:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 01:00:21 PM
- Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast • GlobeNewswire Inc. • 11/29/2023 01:00:00 PM
- Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:15:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:01:00 PM
- Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 12:00:18 PM
- Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM